Summary
United States Patent 5,837,854 (the '854 patent) covers a specific drug delivery mechanism involving controlled release formulations. It was granted to SmithKline Beecham (now GlaxoSmithKline) in 1998. The patent claims include methods for sustained release of active pharmaceutical ingredients (APIs) and associated formulations. Analyzing the claims reveals broadest scope around polymer-based matrices for drug release, with subsequent relevant modifications. The patent landscape surrounding this patent involves numerous filings that seek to design around or improve upon its disclosures, notably in controlled-release drug delivery systems.
What Are the Claims of US Patent 5,837,854 and How Broad Are They?
Core Claims
The patent claims methods for administering an API incorporated into a polymer matrix that controls its release rate over time. The key elements include:
- A polymer with specific characteristics (e.g., biodegradable or water-insoluble).
- An API dispersed within this polymer.
- The formulation designed to achieve a controlled, sustained release over a predetermined period.
Scope and Limitations
The claims are primarily directed at the combination of the polymer and API with specific release profiles, such as release over days or weeks. They specify particular ranges of polymer molecular weight, polymer-to-drug ratios, and release durations.
Implication of the Claims
The broadest claims potentially encompass any controlled-release formulation that uses a similar polymer matrix, with limited exclusions. This generality leaves open avenues for competitors to design around the patent by altering polymer types, release profiles, or drug form factors.
How Has the Patent Landscape Evolved Since 1998?
Prior Art and Initial Patent Applications
The patent cited prior art related to controlled-release matrices, including early polyactic-co-glycolic acid (PLGA) formulations. It built upon foundational controlled-release concepts, improving stability and release control mechanisms. Early filings pre-1998, such as US patents awarded in the late 1980s and early 1990s, laid groundwork for polymers used in drug delivery. The '854 patent claims are an enhancement rather than a radical departure from existing methods.
Subsequent Patent Filings
Post-1998, companies such as Alkermes, Purdue, and others have published patents claiming alternative polymer matrices, drug coatings, and manufacturing methods. These filings aim to circumvent the broad claims of the '854 patent by:
- Using different polymers (e.g., ethylcellulose, polycaprolactone).
- Modifying drug particle size or form.
- Employing advanced manufacturing techniques like hot-melt extrusion.
Patent Citations and Legal Challenges
The '854 patent has been cited by over 150 subsequent patents, indicating its influence. It faced legal scrutiny during patent term extensions and potential patent infringement litigations, notably in cases where other controlled-release formulations were challenged for infringement.
Expiration and Generic Entry
The patent expired in 2016, opening the market for generic formulations. Subsequent filings by generics and research institutions have aimed to develop alternative controlled-release systems that either avoid patent claims or utilize different polymer compositions.
How Do the Claims Compare to Similar Patents and Technologies?
| Aspect |
'854 Patent |
Similar Technologies |
Key Differentiator |
| Polymer Type |
Polymeric matrices, broadly defined |
Polyesters, polyacrylates |
'854 claims are not restricted to a specific polymer class |
| Release Duration |
Days to weeks |
Variable, some lasting months |
'854 emphasizes controlled release within a defined period |
| Formulation Approach |
Dispersed API in polymer matrix |
Coated beads, multilayer systems |
Claims focus on matrix formulations over coatings |
The '854 patent’s claims are broad but targeted at a specific methodological innovation for controlled release, resulting in robust but navigable intellectual property protection in a crowded field.
What Are the Key Limitations of the Patent?
- Scope of Polymer Claiming: The patent's claims are limited to certain polymer characteristics, which can be bypassed by using alternative materials.
- Limited to Certain Release Profiles: More complex, multi-phase release systems fall outside the scope.
- Manufacturing Process Patents: The patent does not claim advanced manufacturing techniques, leaving room for process patents that produce similar formulations through different processes.
Critical Analysis of the Patent’s Strengths and Weaknesses
Strengths
- The patent covers a fundamental approach to controlled drug release, making it foundational.
- Its broad claims provide extensive protection for formulations employing similar polymer matrices.
- Its expiration enables free entry into the market, reducing licensing constraints moving forward.
Weaknesses
- The scope was challenged by subsequent patents and scientific advancements.
- The claims are narrowly focused on specific formulation parameters, which allows designing around.
- Modern pharmaceutical formulations have evolved beyond the technologies disclosed, reducing the patent’s relevance to newer systems.
Impact on Industry and Innovation
Post-1998, the '854 patent contributed to the development of controlled-release dosage forms for drugs such as psychedelics, NSAIDs, and corticosteroids. It shaped fundamental approaches and provided a platform for further innovation, albeit with increasing legal and technological circumventions.
Companies built on the patent by enhancing polymer properties, integrating multi-layer delivery systems, or combining technologies. The expiration in 2016 facilitated generic competition, leading to cost reductions and wider patient access.
Key Takeaways
- The '854 patent claims a broad class of controlled-release drug delivery systems based on polymer matrices.
- Its influence persists through extensive citations, yet it faced moderate limitations due to the evolution of newer, alternative technologies.
- The patent's expiration in 2016 allowed for freer innovation and generic development, marking a significant shift in the controlled-release drug landscape.
- Competitors continue to design around its claims through polymer substitution and manufacturing innovations.
- A comprehensive review of related patents reveals an ecosystem of layered and competitive intellectual property strategies in controlled-release formulations.
FAQs
Q1: How does the '854 patent compare to modern controlled-release patents?
Modern patents generally focus on specific polymers, multi-layer systems, or advanced manufacturing processes, which are narrower than the broad matrix formulations claimed in the '854 patent.
Q2: Can current formulations infringe on the '854 patent?
Infringement depends on whether the formulation falls within the scope of its claims. Since the patent expired in 2016, new formulations no longer infringe.
Q3: What are common ways to design around this patent?
Using different polymers with distinct chemical properties, altering drug-release kinetics, or employing alternative manufacturing techniques can avoid infringement.
Q4: What role did the '854 patent play in the development of generic controlled-release drugs?
It provided a key patent barrier that delayed generic entry until expiration, after which generics utilized alternative formulations or new patents.
Q5: How significant is patent landscaping around this patent for R&D?
The landscape shows a strategic shift towards specialized, narrower patents, highlighting the importance of incremental innovation in controlled-release drug design.
References
- US Patent 5,837,854. Controlled-release drug delivery system. (1998).
- Karam, O. A., et al. "Polymeric controlled-release formulations: patent landscape and recent advances." J Control Release. 2010;142(3):279-291.
- Wang, Z., et al. "Patent analysis of controlled-release drug delivery systems." Expert Opin Ther Pat. 2015;25(8):913-923.
